Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 9, 2013

View Archived Issues

Noninvasive electroencephalograph for functional brain analysis in monkeys

Preclinical evaluation of a mixed-mirror image DNA/RNA aptamer to regulate glucose tolerance

Characterization of an in vitro 3D culture model of human brain development

Data published from phase II evaluations of a troponin activator in patients with ALS

Reductions in rheumatic pain seen with willow bark extract STW-33-1

University of Pennsylvania discloses new ICOS-based CAR inhibitors for cancer

Italian researchers patent novel oligonucleotides for cancer

Researchers at Janssen Pharmaceutica prepare novel endothelial lipase inhibitors

Canadian group patents novel polypeptides binding to prothrombin

CP-9531 demonstrates efficacy for multiple sclerosis

PaxVax begins phase III trial challenge studies for single-dose oral cholera vaccine

Cellular Biomedicine reports phase I/IIa cell therapy trial data for knee osteoarthritis

Exon-skipping compound PRO-053 begins phase I/II trial for Duchenne muscular dystrophy

Sobi acquires full rights to Kineret, additional data for Kepivance

FDA approves Abraxane for advanced pancreatic cancer

Toa Eiyo and Astellas Pharma set to launch Bisono Tape in Japan

Genkyotex obtains IND approval for phase II study of GKT-137831

Diurnal completes pharmacokinetic portion of CATCH trial in congenital adrenal hyperplasia

QRxPharma to discuss MoxDuo NDA with FDA prior to refiling

BIOD-123 demonstrates glycemic control comparable to Humalog in phase II study

FDA grants QIDP designation to Cempra's solithromycin

Baxter completes acquisition of Gambro

GenVec withdraws plan of dissolution

Civitas Therapeutics begins phase IIb study of inhaled levodopa

Cempra's solithromycin well tolerated in patients with chronic liver disease

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...